EUVIMEDEUVIMED entdecken
Crossref

Ferrocene-Conjugated Paclitaxel Prodrug for Combined Chemo-Ferroptosis Therapy of Cancer

Shaojin Lu, Dengyuan Hao, Qian Meng, Biyou Zhang, Xiujuan Xiang, Qing Pei, Zhigang Xie iD

ACS Applied Materials & Interfaces · 11.09.2024 · 16 (36) · 47325-47336

DOI: 10.1021/acsami.4c11418 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 27.08.2024. Verfasst von Shaojin Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, Jilin, P. R. China. Hauptthemen laut MEDLINE: Paclitaxel, Metallocenes, Ferrous Compounds, Prodrugs. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelMetallocenesFerrous CompoundsProdrugsFerroptosisHumansAnimalsMiceCell Line, TumorFemaleMice, Inbred BALB CNanoparticlesApoptosisMice, NudeNeoplasmsAntineoplastic Agents, Phytogenic

Stichwörter der Autor:innen

chemotherapycombinational therapyferroptosispaclitaxelprodrugs

Substanzen

PaclitaxelMetallocenesferroceneFerrous CompoundsProdrugsAntineoplastic Agents, Phytogenic

Autor:innen und Institutionen

  • Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, Jilin, P. R. China.
  • School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei 230026, Anhui, P. R. China.
  • Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, P. R. China.

ORCID-Profile: Zhigang Xie

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Lu, S., Hao, D., Meng, Q., Zhang, B., Xiang, X., Pei, Q., & Xie, Z. (2024). Ferrocene-Conjugated Paclitaxel Prodrug for Combined Chemo-Ferroptosis Therapy of Cancer. ACS Applied Materials & Interfaces, 16(36), 47325-47336. https://doi.org/10.1021/acsami.4c11418

Vancouver

Lu S, Hao D, Meng Q, Zhang B, Xiang X, Pei Q, et al. Ferrocene-Conjugated Paclitaxel Prodrug for Combined Chemo-Ferroptosis Therapy of Cancer. ACS Applied Materials & Interfaces. 2024;16(36):47325-47336. doi:10.1021/acsami.4c11418

BibTeX
@article{Lu2024,
  author = {Lu, Shaojin and Hao, Dengyuan and Meng, Qian and Zhang, Biyou and Xiang, Xiujuan and Pei, Qing and Xie, Zhigang},
  title = {Ferrocene-Conjugated Paclitaxel Prodrug for Combined Chemo-Ferroptosis Therapy of Cancer},
  journal = {ACS Applied Materials & Interfaces},
  year = {2024},
  volume = {16},
  number = {36},
  pages = {47325--47336},
  doi = {10.1021/acsami.4c11418}
}
Kostenlos starten →